Verapamil in patients with cardiovascular disease
Sübutlu məlumatların xülasələri
16.10.2017 • Sonuncu dəyişiklik 16.10.2017
Editors
Verapamil use appears not to be associated with harm in patients with myocardial infarction.
A systematic review including 66 studies was abstracted in DARE. Combined relative risk of reinfarction ranged from 0.79 to 0.80 in favour of verapamil. The range of the effect of mortality ranged from a 5.6% increase to a 18.5% reduction, the combined odds reduction favouring verapamil.
Ədəbiyyat
- Pepine CJ, Faich G, Makuch R. Verapamil use in patients with cardiovascular disease: an overview of randomized trials. Clin Cardiol 1998 Sep;21(9):633-41.